HRID2091875

反应详情

EQUATION

反应方程式

REACTANTS

反应物

结构：CC1(C)OB(c2c(F)ccc3c2ccn3[Si](C)(C)C(C)(C)C)OC1(C)C

HCID57506725

未命名化合物

结构：Clc1nc(N2CCOCC2)c2nc(CN3CCC(C4COC4)CC3)ccc2n1

HCID58405033

未命名化合物

PRODUCTS

生成物

结构：Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2nc(CN3CCC(C4COC4)CC3)ccc2n1

HCID58404962

未命名化合物

PROCEDURE

实验过程

4-(2-chloro-6-((4-(oxetan-3-yl)piperidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)morpholine (0.11 g) was reacted with 1-(tert-butyldimethylsilyl)-5-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole via General Procedure A to produce 59.8 mg of 130 following reverse phase HPLC purification.

WORKUP

后处理

customto produce
custom59.8 mg of 130 following reverse phase HPLC purification

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-2c4fd9851b784c9aaf4ae63dcdb9fcb9
来源数据集: uspto-grants-2013_05
DOI: 10.6084/m9.figshare.5104873.v1
专利: US08440651B2
来源说明: uspto-grants-2013_05

反应 SMILES

Cl[C:2]1[N:3]=[C:4]([N:23]2[CH2:28][CH2:27][O:26][CH2:25][CH2:24]2)[C:5]2[N:11]=[C:10]([CH2:12][N:13]3[CH2:18][CH2:17][CH:16]([CH:19]4[CH2:22][O:21][CH2:20]4)[CH2:15][CH2:14]3)[CH:9]=[CH:8][C:6]=2[N:7]=1.[Si]([N:36]1[C:44]2[C:39](=[C:40](B3OC(C)(C)C(C)(C)O3)[C:41]([F:45])=[CH:42][CH:43]=2)[CH:38]=[CH:37]1)(C(C)(C)C)(C)C>>[F:45][C:41]1[C:40]([C:2]2[N:3]=[C:4]([N:23]3[CH2:28][CH2:27][O:26][CH2:25][CH2:24]3)[C:5]3[N:11]=[C:10]([CH2:12][N:13]4[CH2:18][CH2:17][CH:16]([CH:19]5[CH2:22][O:21][CH2:20]5)[CH2:15][CH2:14]4)[CH:9]=[CH:8][C:6]=3[N:7]=2)=[C:39]2[C:44](=[CH:43][CH:42]=1)[NH:36][CH:37]=[CH:38]2